1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,536 | 0,578 | 22:18 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.12.25 | Mendus AB: Report from the Extraordinary General Meeting of Mendus AB (publ) on 16 December 2025 | 155 | GlobeNewswire (Europe) | At the extraordinary general meeting (the "EGM") of Mendus AB (publ), reg. no. 556629-1786, (the "Company"), on 16 December 2025 adopted, inter alia, the following resolutions. For more detailed information... ► Artikel lesen | |
| 10.12.25 | Mendus - ASH 2025 update supports renewed strategy | 332 | Edison Investment Research | Mendus has presented incremental clinical data for vididencel at the American Society of Hematology (ASH) 67th Annual Meeting, involving long-term follow-up for the ADVANCE II trial. This study is testing... ► Artikel lesen | |
| 01.12.25 | 59 NORTH COMMUNICATIONS: NorthX Biologics achieves milestone GMP certification to manufacture vididencel - Mendus' lead cell therapy product for acute and chronic myeloid leukemias | 4 | Cision News | ||
| MENDUS Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | Mendus AB: Mendus Announces Large-Scale Vididencel GMP Production Milestone in Manufacturing Alliance with NorthX Biologics | 130 | GlobeNewswire (Europe) | Mendus AB (publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the successful establishment of large-scale GMP production of its lead product... ► Artikel lesen | |
| 27.11.25 | Mendus - Ovarian cancer: another shot at goal | 307 | Edison Investment Research | Mendus has reported encouraging long-term data from its Phase I ALISON trial, which is investigating its lead off-the-shelf cancer vaccine, vididencel, in high-risk ovarian cancer (OC). The latest update... ► Artikel lesen | |
| 27.11.25 | Mendus AB: ALISON trial long-term follow-up confirms safety, tolerability and feasibility of vididencel as an active immunotherapy in high-risk ovarian cancer | 141 | GlobeNewswire (Europe) | Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces positive 2-year follow-up data from the ALISON Phase 1 trial. The data... ► Artikel lesen | |
| 21.11.25 | Edison Group: Edison Issues Report on Mendus (IMMU) | 288 | Newsfile | London, United Kingdom--(Newsfile Corp. - November 21, 2025) - Edison issues report on Mendus (OMX: IMMU).We have updated our investment view on Mendus following its expanded strategy for vididencel... ► Artikel lesen | |
| 20.11.25 | Mendus - New strategy broadens vididencel potential | 259 | Edison Investment Research | We have updated our investment view on Mendus following its expanded strategy for vididencel to chronic myeloid leukaemia (CML) and a broader acute myeloid leukaemia (AML) population, including chemo-eligible... ► Artikel lesen | |
| 13.11.25 | Mendus - New strategy underway; Q325 results | 261 | Edison Investment Research | Mendus has reported its Q325 results, following its recently announced renewed strategy to broaden the potential for its lead cancer vaccine, vididencel, to include both acute myeloid leukaemia (AML)... ► Artikel lesen | |
| 13.11.25 | Mendus AB: Mendus AB Interim Report January - September 2025 | 119 | GlobeNewswire (Europe) | Updated clinical development strategy based on positive data
In the third quarter of 2025, Mendus shaped up its clinical development plans for the lead program vididencel in myeloid malignancies.The... ► Artikel lesen | |
| 02.10.25 | Mendus - New strategy to include CML alongside AML | 368 | Edison Investment Research | Mendus has announced a strategy update, unveiling plans to expand the application of vididencel beyond the current lead programme in acute myeloid leukaemia (AML), to chronic myeloid leukaemia (CML).... ► Artikel lesen | |
| 02.10.25 | Mendus AB: Mendus announces updated clinical strategy and operational focus | 202 | GlobeNewswire (Europe) | Vididencel to be developed as a post-remission therapy across AML risk categories and in CML
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor... ► Artikel lesen | |
| 22.08.25 | Mendus - Steady progress throughout Q225 | 401 | Edison Investment Research | Mendus's Q225 results reflect a period of progress across the pipeline. The lead programme, vididencel in acute myeloid leukaemia (AML), remains on track to be pivotal-stage ready in H225, creating... ► Artikel lesen | |
| 21.08.25 | Mendus - Clinical activities on track | 399 | Edison Investment Research | Mendus has reported its Q225 results. During the period, it made continued progress on the lead programme (vididencel in acute myeloid leukaemia, AML), which remains on track to be pivotal-stage ready... ► Artikel lesen | |
| 21.08.25 | Mendus AB: Mendus AB Interim Report January - June 2025 | 168 | GlobeNewswire (Europe) | Expanding the vididencel opportunity
In the second quarter of 2025, Mendus reported data from the pivotal Phase 2a ADVANCE II trial at different keynote conferences, confirming that its lead product... ► Artikel lesen | |
| 23.07.25 | Mendus - Strengthened IP profile in ovarian cancer | 454 | Edison Investment Research | Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the granting of a new US patent covering its use in ovarian cancer (OC). While the lead programme for... ► Artikel lesen | |
| 23.07.25 | Mendus AB: Mendus granted US patent for use of vididencel in ovarian cancer | 169 | GlobeNewswire (Europe) | Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence in life-threatening cancers, today announces that the United States Patent and... ► Artikel lesen | |
| 02.06.25 | Mendus - Another encouraging ovarian cancer update | 380 | Edison Investment Research | Mendus presented a positive clinical update for its Phase I ALISON trial in ovarian cancer at the 61st Annual American Society of Clinical Oncology conference (ASCO 2025). Importantly, the data demonstrated... ► Artikel lesen | |
| 07.05.25 | Mendus - No surprises in Q125 update | 352 | Edison Investment Research | Mendus's Q125 results came in as expected, with management confirming that vididencel (in acute myeloid leukaemia, AML) is on track to be pivotal-stage ready from H225. Recent highlights include regulatory... ► Artikel lesen | |
| 06.05.25 | Mendus - Plans falling into place for vididencel pivotal study | 498 | Edison Investment Research | Mendus's Q125 report included no surprises, with the company staying on track to secure large-scale GMP production of vididencel and Phase III readiness by H225, which we see as the most significant... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 100,70 | -0,30 % | Neue Zölle für AMD, OpenAI kauft bei der Konkurrenz von Nvidia, Rheinmetall weiter im Aufwind und BioNTech schürt neue Hoffnung | Die Börsen bleiben weiterhin geprägt von hohen Kursständen, wenngleich es hier und dort auch etwas Gegenwind zu verzeichnen gibt. Nicht jede vielbeachtete Aktie kann derzeit schon neue Rekorde schreiben.... ► Artikel lesen | |
| EVOTEC | 6,190 | +4,45 % | EQS-PVR: Evotec SE: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Evotec SE
Evotec SE: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
16.01.2026 / 10:33 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BB BIOTECH | 53,10 | +2,31 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| MEDIGENE | 0,044 | -22,81 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| AMGEN | 295,45 | +0,51 % | Amgen(AMGN): Ausbruch geglückt - Warum Trader jetzt die Marke von 345 USD genau im Auge behalten. | Perfekte Einstiegschance nach dem Pullback? Rückblick Amgen ist ein führendes Biotechnologieunternehmen und setzt stark auf Medikamente wie MariTide (Gewichtsverlust-Kandidat), das direkt mit den Produkten... ► Artikel lesen | |
| NOVAVAX | 8,358 | -1,29 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,940 | -3,29 % | HEIDELBERG PHARMA AG - Schwäche mit Signalwirkung | ||
| ILLUMINA | 131,00 | +0,35 % | Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Tuesday announced that the Centers for Medicare and Medicaid Services or CMS has granted reimbursement for the company's FDA-approved in vitro diagnostic... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 642,00 | +0,12 % | Evercore ISI raises Regeneron stock price target to $875 on Dupixent growth | ||
| AAP IMPLANTATE | 1,530 | 0,00 % | AAP Implantate AG - Stabilität als strategische Zone | ||
| CO.DON | 0,020 | -11,11 % | EQS-PVR: CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: CO.DON AG
CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.01.2026 / 12:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BIOXXMED | 1,024 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,290 | -0,77 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 0,880 | +2,27 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen |
Das Unternehmen MENDUS AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,537 Euro und damit +12,34 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MENDUS AB finden Sie auf Wallstreet Online.